It was remarkable to develop a vaccine during a pandemic in a couple of months rather than years. Now the race is on to get billions of doses from several manufacturers distributed soon enough to stop the virus's spread. Governments have spent a lot of money on the vaccination endeavor, so it's not only human lives on the line. Here are 5 pharma company stocks working on COVID-19 vaccines.
5 Pharma Company Stocks Working on a Coronavirus Vaccine
|Pharma Company||Current Market Price||Vaccine|
|Dr. Reddy's Laboratories||Rs 4,903||Sputnik V|
|Wockhardt||Rs 419||Sputnik V|
|Panacea Biotec||Rs 312||Sputnik V|
|Cadila Healthcare||Rs 552||ZyCov-D|
|Cipla||Rs 944 76.||Moderna|
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories stock is in the spotlight today as the pharma giant announced that it has reached an agreement to sell its rights to an anti-cancer medication to Citius Pharmaceuticals of the United States. Apart from that, the corporation has stated that it will launch the Sputnik V vaccine, which is made in India, in India between September and October of this year.
If the Sputnik V vaccine gains widespread approval, it will benefit the company in the medium term, especially if it becomes a big exporter this year.
Despite the fact that pricing pressure in the US markets has been easing, the incoming administration in the United States has a track record of lowering medicine prices. If this were to happen on a regular basis, export margins might be harmed. Because of the low margins in Q1-FY22, the price risk has resurfaced.
Dr. Reddy's Laboratories exercised stock options and distributed 14,284 fully paid up equity shares worth Rs 7.28 crore to various workers. According to a regulatory filing, the ESOP consists of 6,774 equity shares of Rs 5 each under the Dr. Reddy's Employees Stock Option Scheme and 7,510 equity shares of Rs 5 each under the ADR Stock Option Scheme.
The stock returned 86.74 percent over three years, compared to 48.94 percent for the Nifty 100. Over a three-year period, the stock achieved an 86.74 percent return, compared to 36.87 percent for Nifty Pharma.
Wockhardt previously announced that it had reached an agreement for the manufacture and supply of the Sputnik V/Sputnik Light vaccine against Covid-19 with Enso Healthcare DMCC (Enso), a company based in Dubai, UAE, and Human Vaccine LLC (HV), a wholly owned subsidiary of the Russian Federation's sovereign wealth fund (RDIF).
The single-dose Sputnik Light Covid-19 vaccine is likely to launch shortly in India, according to Russian diplomat Nikolay Kudashev, as quoted by news agency ANI.
Only 4.14 percent of trading sessions in the last 16 years had intraday drops of more than 5%. In the fiscal year ended March 31, 2021, the company delivered a ROE of 20.31 percent, surpassing its five-year average of -2.56 percent. The company's QoQ revenue increase was 34.67 percent, the greatest in the prior three years. Over a three-year period, the stock returned -37.79 percent, while Nifty Pharma returned 36.87 percent to investors.
Panacea Biotec's stock jumped 5.74 percent to Rs 311.50 after the business announced the first shipment of 1 million doses of the second component of Panacea Biotec's Russian Sputnik V coronavirus vaccine for sale in India.
This is the first batch of the company's second component, which is manufactured and supplied in India. Panacea Biotec's state-of-the-art vaccine manufacturing plant in Himachal Pradesh produced the doses for the second component of Sputnik V.
Stock returned 20.82 percent over three years, compared to 39.62 percent for the Nifty Smallcap 100. Over a three-year period, the stock returned 20.82 percent, while Nifty Pharma returned 36.87 percent to investors.
The Moderna vaccine will be available as a ready-to-use injectable vaccine starting in. After the vial is opened, it can be stored for seven months at a specified temperature and for 30 days at room temperature.
Nonetheless, the company's Chief Monetary Officer has acknowledged that there is currently "nothing conclusive."
Moderna and the Indian government are working together to determine the vaccine's indemnification points. 14 days following the first dosage, the Moderna vaccine had a 94.1 percent efficacy rate.
Cipla's web revenue increased by 24% year over year in the second quarter of 2021. The company's revenue also increased by 27% year over year, thanks to a jump in demand for Covid-19 medications as a result of the pandemic's second wave.
With Remdesivir, Favipiravir, and Toclizumab, the business has been aggressive in creating a Covid-care portfolio. As covid cases rise again, their influence should be noticeable until the first half of FY 22. The company has an opportunity to pursue because one of its primary advantages is its inexpensive price.
According to a health ministry official, Cadila Healthcare, a pharmaceutical business, would begin providing coronavirus vaccine to children aged 12 to 17 in October.
Before the Zydus Cadila vaccine is handed out in October, the details of the Covid-19 immunization for youngsters aged 12 to 17, including prioritizing those with health difficulties, will be announced, according to reports.
According to the Department of Biotechnology (DBT), ZyCoV-D is the world's first DNA-based coronavirus vaccine, which when administered creates the SARS-CoV-2 virus's spike protein and stimulates an immune response that aids in disease prevention and viral clearance.
The stock returned 30.73 percent over three years, compared to 48.94 percent for the Nifty 100.
Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage houses are not liable for any losses caused as a result of decisions based on the article. The above article is for informational purposes only and is picked from the brokerage report of Sharekhan.